PMID- 18473994
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20211203
IS  - 1574-8871 (Print)
IS  - 1574-8871 (Linking)
VI  - 2
IP  - 2
DP  - 2007 May
TI  - Clinical development of mTOR inhibitors: a focus on lymphoma.
PG  - 103-10
AB  - The mammalian target of rapamycin (mTOR) kinase is positioned at the juncture of 
      several pathways regulating cell growth and proliferation. It is the downstream 
      effector of the oncogenic PI3K/Akt pathway and is a key regulator of 
      translational initiation. Accumulating data support mTOR's role in 
      lymphomagenesis, and its inhibition in preclinical models leads to lymphoma 
      regression. The rationale for testing mTOR inhibitors in patients with lymphoma 
      is evident, and early clinical data is promising. Along with the prototype of 
      mTOR inhibitors, rapamycin, there are three mTOR inhibitors furthest along in 
      development: temsirolimus, everolimus, and AP23573. These agents are emerging as 
      well-tolerated drugs with encouraging preliminary activity. Here we review the 
      rationale for testing mTOR inhibitors in lymphoma, the phase 1 trials influencing 
      dose and schedule of mTOR inhibitors, and summarize the clinical results in 
      obtained to date in patients with lymphoma.
FAU - Smith, Sonali M
AU  - Smith SM
AD  - The University of Chicago Hospitals, Chicago, IL 60637, USA. 
      msmith@medicine.bsd.uchicago.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Rev Recent Clin Trials
JT  - Reviews on recent clinical trials
JID - 101270873
RN  - 0 (Antineoplastic Agents)
RN  - 48Z35KB15K (ridaforolimus)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Everolimus
MH  - Humans
MH  - Lymphoma/*drug therapy
MH  - Protein Kinases/*drug effects
MH  - Sirolimus/*analogs & derivatives/pharmacology
MH  - TOR Serine-Threonine Kinases
RF  - 82
EDAT- 2008/05/14 09:00
MHDA- 2008/06/18 09:00
CRDT- 2008/05/14 09:00
PHST- 2008/05/14 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2008/05/14 09:00 [entrez]
AID - 10.2174/157488707780599366 [doi]
PST - ppublish
SO  - Rev Recent Clin Trials. 2007 May;2(2):103-10. doi: 10.2174/157488707780599366.